Antibody Sequencing

Unlock the full potential of your antibody discovery pipeline with our cutting-edge sequencing solutions. Hybridoma technology has paved the way for generating diverse, high-quality antibodies, but the unpredictability of hybridoma stability can put your hard-earned antibodies at risk. That’s why at Immunovive, we offer a proactive approach—sequencing the variable regions of both heavy and light chains from hybridoma cells as soon as possible after fusion.

Our streamlined process begins with RNA extraction from hybridomas, followed by precise PCR amplification of the variable regions. We then clone the amplified DNA into specialized sequencing vectors and determine the exact sequence using trusted Sanger Sequencing. Advanced bioinformatics tools reveal the full antibody protein sequence, giving you a permanent, secure record for future innovation.

With this sequence in hand, you’re empowered to create custom expression constructs, develop next-generation therapeutics, engineer bi-specifics, design anti-idiotype antibodies, produce CAR T-cells, and more—all with confidence and agility.

Partner with Immunovive to safeguard your antibody assets and open doors to innovation. Contact us today to explore how our sequencing capabilities can accelerate your scientific success.